This article is more than 5 years old. Information may no longer be current.
Similar results seen with liposomal bupivacaine injection vs modified Ranawat suspension after TKA
Click Here to Manage Email Alerts
In addition to providing pain relief, narcotic usage and range of motion similar to that with the use of a modified Ranawat suspension after total knee arthroplasty, liposomal bupivacaine used as a periarticular injection trended toward improved walking distances for patients.
Researchers prospectively collected data on 105 patients who underwent total knee arthroplasty. Of the group, 54 patients received an intraoperative injection of liposomal bupivacaine and 51 patients received a modified Ranawat suspension. At 24 hours, 48 hours, 72 hours, 2 weeks and 6 weeks, investigators collected and recorded outcome measures and pain levels.
Results showed patients were not significantly different with regard to the surgical approach, length of stay and discharge to home or rehab. Investigators also noted the groups were not significantly different with regard to pain at rest and with activity during the time intervals. The liposomal bupivacaine group had a greater consumption of narcotics compared with the modified Ranawat suspension group initially, but this difference was not statistically significant after postoperative day 2. The groups were not significantly different with regard to active knee range of motion, according to researchers.
“Although there were improved walking distances with the liposomal bupivacaine group, this was not found to be statistically significant,” the authors wrote. ‒ by Monica Jaramillo
Disclosures: Collis reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts